GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » Degree of Operating Leverage

KROS (Keros Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Keros Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.00. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Keros Therapeutics's Degree of Operating Leverage or its related term are showing as below:

KROS's Degree of Operating Leverage is not ranked *
in the Biotechnology industry.
Industry Median: -0.02
* Ranked among companies with meaningful Degree of Operating Leverage only.

Keros Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Keros Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics Degree of Operating Leverage Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - 0.01

Keros Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of Keros Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Keros Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keros Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's Degree of Operating Leverage falls into.


;
;

Keros Therapeutics Degree of Operating Leverage Calculation

Keros Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 13.47 (Mar. 2025) / -162.606 (Mar. 2024) - 1 )/( 214.713 (Mar. 2025) / 0.234 (Mar. 2024) - 1 )
=-1.0828/916.5769
=-0.00***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Keros Therapeutics  (NAS:KROS) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Keros Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Keros Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Executives
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith Regnante officer: Chief Financial Officer 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey officer: Chief Scientific Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi officer: Chief Operating Officer C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles director C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director, 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Tomer Kariv director, 10 percent owner C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jasbir Seehra director, officer: Chief Executive Officer C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421